title: Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
abstract: Nanomedicine promises to enhance the ability of clinicians to address some of the serious challenges responsible for cardiovascular mortality, morbidity and numerous societal consequences. Targeted imaging and therapy applications with perfluorocarbon nanoparticles are relevant to a broad spectrum of cardiovascular diseases, ranging from asymptomatic atherosclerotic disease to acute myocardial infarction or stroke. As illustrated in this article, perfluorocarbon nanoparticles offer new tools to recognize and characterize pathology, to identify and segment high-risk patients and to treat chronic and acute disease.
authors: Division of Cardiology, Washington University Medical School, Cortex Building, St Louis, MO 63108, USA. greg@cvu.wustl.edu
authors: Gregory M
authors: GM
authors: Lanza
authors: Patrick M
authors: PM
authors: Winter
authors: Shelton D
authors: SD
authors: Caruthers
authors: Michael S
authors: MS
authors: Hughes
authors: Tillmann
authors: T
authors: Cyrus
authors: Jon N
authors: JN
authors: Marsh
authors: Anne M
authors: AM
authors: Neubauer
authors: Kathy C
authors: KC
authors: Partlow
authors: Samuel A
authors: SA
authors: Wickline
mesh_terms: D000818:Animals; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D005466:Fluorocarbons / Q000737:chemistry*; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D004337:Drug Carriers; D005466:Fluorocarbons; D004364:Pharmaceutical Preparations